The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berwin, B.
Right arrow Articles by Nicchitta, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berwin, B.
Right arrow Articles by Nicchitta, C. V.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2002, 168: 4282-4286.
Copyright © 2002 by The American Association of Immunologists

Cutting Edge

Cutting Edge: CD91-Independent Cross-Presentation of GRP94(gp96)-Associated Peptides1

Brent Berwin*, Justin P. Hart{dagger}, Salvatore V. Pizzo{dagger} and Christopher V. Nicchitta2,*

Departments of * Cell Biology and {dagger} Pathology, Duke University Medical Center, Durham, NC 27710


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
GRP94(gp96) elicits CD8+ T cell responses against its bound peptides, a process requiring access of its associated peptides into the MHC class I cross-presentation pathway of APCs. Entry into this pathway requires receptor-mediated endocytosis, and CD91 (low-density lipoprotein receptor-related protein) has been reported to be the receptor mediating GRP94 uptake into APC. However, a direct role for CD91 in chaperone-based peptide Ag re-presentation has not been demonstrated. We investigated the contribution of CD91 to GRP94 cell surface binding, internalization, and trafficking in APCs. Whereas a clear role for CD91 in {alpha}2-macroglobulin binding and uptake was readily obtained, the addition of excess CD91 ligand, activated {alpha}2-macroglobulin, or receptor-associated protein, an antagonist of all known CD91 ligands, did not affect GRP94 cell surface binding, receptor-mediated endocytosis, or peptide re-presentation. These data identify a CD91-independent, GRP94 internalization pathway that functions in peptide Ag re-presentation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
The molecular chaperone GRP94(gp96) is one of several molecular chaperones that have been shown to elicit antitumor responses in murine models (1, 2, 3, 4, 5). Recent studies demonstrate that GRP94 functions in both prophylactic and therapeutic protocols to reduce or eliminate tumor growth and progression. The basis for the immunological capabilities of these proteins is thought to reflect two intrinsic properties: 1) they act as general adjuvants to the innate immune system, promoting the maturation and activation of dendritic cells and macrophages and eliciting cytokine secretion (2, 6, 7); and 2) as vehicles for associated peptides, they deliver their bound Ags to professional APCs, to yield peptide-specific T cell stimulation (8, 9, 10, 11). This latter function is thought to reflect high-affinity, cell surface chaperone receptors on APCs, which direct GRP94 into the MHC class I re-presentation pathway. It is exclusively the receptor-mediated pathway that is reported to function in the re-presentation of GRP94-associated peptides (8).

Recently, a member of the low-density lipoprotein (LDL)3 family of scavenger receptors, CD91 ({alpha}2-macroglobulin ({alpha}2M) receptor; LDL receptor-related protein), was proposed to serve as the unique receptor responsible for directing GRP94 into the class-I Ag processing pathways of APCs (12, 13, 14). The conclusion that CD91 functions as the GRP94 receptor stems from the observation that {alpha}2M, the active form ({alpha}2M*) of which is an established, endogenous ligand for CD91, abrogates GRP94-mediated, APC-dependent T cell stimulation (12). Although consistent with a role for CD91 in GRP94-based Ag re-presentation, previous observations call into question whether the effects of CD91-directed ligands on GRP94-based peptide re-presentation reflect a direct role of CD91 in chaperone uptake and processing. Primarily, CD91 is expressed on a diverse array of cell types, including fibroblasts and hepatocytes, the majority of which do not function as professional APCs (15). Additionally, in affinity chromatography and chemical cross-linking studies of GRP94-interacting proteins, GRP94 was recovered with a single proteolytic product of CD91; no interactions of GRP94 with intact CD91 were reported (12).

In the present study, CD91 function in the receptor-mediated endocytosis and trafficking of GRP94 in APCs was analyzed. It is well established that ligand binding functions of CD91 are regulated by receptor-associated protein (RAP) (16, 17, 18), which efficiently blocks the cell surface binding and uptake of all known CD91 ligands (16, 17, 18, 19). We report in this work that the binding of GRP94 to APC cell surface receptors was RAP and {alpha}2M*-insensitive. Furthermore, CD91 and its ligand, Pseudomonas exotoxin, segregated from receptor-internalized GRP94 in early compartments of the endocytic pathway. Additionally, re-presentation of GRP94-associated peptides was {alpha}2M* insensitive. These data identify a primary, CD91-independent re-presentation pathway for GRP94-associated peptides in APCs.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Cells and tissue culture

C57BL/6 mice (Charles River Breeding Laboratories, Wilmington, MA) were used to prepare thioglycolate-elicited peritoneal macrophages. Macrophages were harvested 4–5 days postinjection and enriched by adherence selection.

Protein purification and labeling

GRP94 was purified by the method of Wearsch and Nicchitta (20). Pseudomonas exotoxin was obtained from Sigma-Aldrich (St. Louis, MO). Texas Red-, biotin-, and fluorescein-succinymidyl esters (Molecular Probes, Eugene, OR) were used to label proteins according to manufacturer’s protocols. Abs against Kb-OVA complex (25-D1.16) and CD91 were the kind gifts of Dr. J. Yewdell (National Institutes of Health, Bethesda, MD) and Dr. S. Argraves (University of South Carolina, Charleston, SC), respectively.

{alpha}2M was purified as previously described (21). Purified {alpha}2M was converted to the CD91-binding, thiol ester-cleaved derivative ({alpha}2M*) by incubation with 0.2 M NH4HCO3. {alpha}2M* was then labeled with Alexa Fluor (Molecular Probes). RAP was purified as previously described (22). Dr. J. Herz (University of Texas Southwestern Medical Center, Dallas, TX) kindly provided pGEX-RAP expression vectors.

Cell surface binding and uptake

Receptor-mediated uptake reactions were performed as described previously (23). For confocal microscopy analysis, cells were fixed in 4% paraformaldehyde and mounted under 10% PBS, 90% glycerol, and 1 mg/ml phenylenediamine.

Biotin-GRP94 cell surface receptor binding interactions were analyzed by incubating 106 cells/assay with increasing concentrations of biotin-GRP94 for 30 min on ice. Cells were then washed and resuspended in SDS-PAGE sample buffer, and extracts were prepared for SDS-PAGE. Following transfer to nitrocellulose membranes, biotin-GRP94 levels were determined by ECL, following avidin-HRP detection of biotin-GRP94. Quantification of cell surface-bound biotin-GRP94 was determined against a standard curve prepared from serial dilutions of biotin-GRP94.

Adherent macrophages were incubated at 4°C in RPMI 1640, 0.5% BSA for 30 min with the following ligands: fluorescein-GRP94 and Alexa-{alpha}2M* in the presence or absence of RAP. For competition assays final concentrations used were 25 nM for GRP94 and {alpha}2M* and 2500 nM for RAP (100-fold molar excess). After the 30-min binding period, macrophages were washed and then fixed in 4% paraformaldehyde/PBS. Following fixation, the cells were rinsed and unreacted paraformaldehyde was quenched with 0.05 M NH4Cl. Coverslips were then mounted onto slides in mounting medium. All images were obtained on a Zeiss LSM 410 laser scanning confocal microscope (Thornwood, NY) using Zeiss LSM version 3.95 software. All image size and contrast adjustments were performed with PhotoShop (version 4) software (Adobe Software, Palo Alto, CA).

For study of CD91 binding and RAP competition by FACS, adherent macrophages were incubated for 30 min at 4°C with fluorescein-GRP94 or {alpha}2M*-AF488, in the presence or absence of RAP. Ligand and RAP concentrations were as indicated above. Following incubation, cells were rinsed and fixed in 1% paraformaldehyde. Cells were analyzed for fluorescence by FACS and analysis was performed using CellQuest (BD Biosciences, San Jose, CA).

Chaperone-based re-presentation

Peptide re-presentation assays were performed with GRP94 complexed with SIINFEKL peptide (by heat shock, 15 min at 50°C) (24, 25) and subsequently isolated from free peptide by Sephadex G-75 size exclusion chromatography (Sigma-Aldrich, St. Louis, MO). This preparation does not contain free peptide (26). To assay GRP94/peptide re-presentation, GRP94/peptide complexes and, where indicated, {alpha}2M* were incubated with elicited primary peritoneal macrophages and, following a 3-h incubation at 37°C, subsequently stained with 25-D1.16 Ab (27). The cells were then fixed in 2% paraformaldehyde for FACS analysis.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
Trafficking itineraries of GRP94 and CD91

CD91 has been identified as the unique receptor responsible for directing GRP94 into MHC class I re-presentation pathways of APCs (12, 13, 14). CD91 is a member of the LDL family of lipoprotein receptors, which bind and internalize an array of ligands, the majority of which are targeted to lysosomes (28). Because little is known regarding the CD91-dependent trafficking of GRP94, the trafficking itineraries of CD91, GRP94, and known CD91 ligands were examined.

To evaluate the subcellular trafficking of CD91 ligands, the trafficking pattern of GRP94 was compared with that of Pseudomonas exotoxin, an obligate CD91 ligand (29). In these experiments, fluor-labeled GRP94 and Pseudomonas exotoxin were bound to macrophage cell surface receptors, the cells were washed, and the staining pattern was analyzed following warming to 37°C. As is evident in Fig. 1GoA, receptor-internalized GRP94 (red channel) and Pseudomonas exotoxin (green channel) were trafficked to distinct subcellular compartments. The lack of costaining suggested that GRP94 and CD91 were rapidly segregated upon internalization to yield distinct trafficking itineraries. To examine this hypothesis, we determined whether, at early time points, internalized GRP94 and CD91 colocalized. Surprisingly, and as shown in Fig. 1GoB, GRP94 (red channel) taken up by receptor-mediated endocytosis did not colocalize with internalized CD91 (green channel). This is in direct contrast to the colocalization observed of receptor-internalized GRP94 and IgG (Fig. 1GoC), which traffic to a FcR+rab5a- endosomal compartment (26). In interpreting these data with respect to a role for CD91 in chaperone-mediated cross-presentation, it is important to note that a functional role for CD91 in this process has been proposed not on the basis of direct trafficking studies but rather from the observed inhibition of peptide re-presentation by CD91-specific Abs and by {alpha}2M competition (12). To reconcile these differences, a direct analysis of CD91 function in GRP94 cell surface binding and uptake was performed.



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 1. Divergent trafficking pathways for GRP94, CD91, and Pseudomonas exotoxin. Texas Red (TR)-GRP94 and fluorescein (Fl)-labeled Pseudomonas exotoxin (PE) (A), fluorescein-labeled Abs against CD91 (B), or fluorescein-labeled IgG (C) were bound to primary peritoneal macrophage cell surface receptors on ice, the cells were washed, and receptor-mediated uptake was initiated by warming the cells to 37°C. After a 30-min (A) or 7-min (B and C) trafficking period, cells were processed for confocal microscopy. Colocalization is observed in the two-channel merge as yellow.

 
Analysis of LDL receptor-related protein family activity in receptor-mediated uptake of GRP94

CD91 is expressed on a diverse array of cell types, including, but not limited to, APCs (15). Previously, we reported that HepG2, a CD91-positive human hepatoma cell line, did not display GRP94 cell surface binding (23, 30). To examine whether there was a positive correlation between CD91 expression and cell surface binding of GRP94, these two parameters were evaluated in an additional CD91-positive cell line, Chinese hamster ovary (CHO), and in RAW264.7 macrophages, a cell line that is CD91 positive and that binds GRP94 (12, 23, 31, 32). As depicted in Fig. 2GoA, both CHO and RAW264.7 cells express nearly identical levels of CD91, findings consistent with previous reports (14, 31, 32). However, though both cell types were CD91 positive, only RAW264.7 cells display appreciable cell surface binding of GRP94; thus, as previously concluded with regard to HepG2 cells, a positive correlation between CD91 expression and GRP94 cell surface binding could not be demonstrated.



View larger version (47K):
[in this window]
[in a new window]
  		FIGURE 2. CD91-independent cell surface binding of GRP94 to elicited macrophages. A, CHO and RAW264.7 macrophages were incubated with fluorescein-GRP94 on ice, the unbound GRP94 was removed, and the cells were subsequently decorated with anti-CD91 mAb (rhodamine channel). Bound GRP94 and CD91 levels were determined by FACS. B, Fluorescein-GRP94 binding to the cell surface of RAW264.7 macrophages was conducted in the presence of BSA, BSA plus {alpha}2M* (400 µg/ml), or DMEM plus 10% bovine serum, followed by FACS analysis. Inset, Scatchard analysis of GRP94 binding to macrophages. GRP94 exhibits a Kd of ~2 x 10-7 M to macrophages, occupying ~106 high-affinity sites per cell. C, The effects of the CD91 ligand {alpha}2M* on the receptor-mediated internalization of GRP94 was examined in RAW264.7 macrophages. Fluorescein-GRP94 was allowed to bind to RAW264.7 macrophages in the presence of 200 µg/ml {alpha}2M*, the free ligand was removed, and the cells were subsequently warmed to 37°C for 7 min to promote internalization.

 
Subsequently, the capacity of the CD91 ligand, {alpha}2M*, to compete for GRP94 cell surface binding was examined. Previously, Binder et al. (12) reported that {alpha}2M efficiently inhibits re-presentation of GRP94-associated peptides, as assayed using peptide-dependent stimulation of T cells as a surrogate for receptor function in GRP94 peptide uptake. This observation is surprising, as CD91 ligands generally do not cross-compete for binding (28). However, a second high-affinity {alpha}2M* binding site has been demonstrated on the surface of APCs (33); thus, it was considered that GRP94 cell surface binding was conferred by this related activity. Therefore, we performed competition experiments with highly purified {alpha}2M*, the CD91 binding form of {alpha}2M, or serum, which contains ~2 mg/ml {alpha}2M (34). As shown in Fig. 2GoB, BSA, BSA supplemented with {alpha}2M*, and DMEM plus 10% serum had no effect on the binding of GRP94 to thioglycolate-elicited macrophages. Indeed, GRP94 was observed to bind to and be internalized by elicited macrophages in the presence of 200 µg/ml {alpha}2M* (Fig. 2GoC). High-affinity binding of GRP94 to macrophage cell surfaces has previously been shown to be specific (8, 13) and saturable (Fig. 2GoB). Because {alpha}2M* constitutes ~1% of total {alpha}2M (35),the {alpha}2M* levels (200 µg/ml) used in these experiments are equivalent to a total {alpha}2M concentration of 20 mg/ml, a concentration in vast excess to that necessary for competition at a shared site(s).

Re-presentation of GRP94-associated peptides via a CD91-independent pathway

RAP is a 39-kDa protein that acts as a universal antagonist to all known CD91 ligands, including {alpha}2M* (16, 17, 19). If CD91 functions in the internalization of GRP94, and as {alpha}2M has been reported to block the interaction of GRP94 with CD91, RAP would be predicted to antagonize the binding of GRP94 to APCs. Therefore, we tested the effects of RAP on cell surface binding of GRP94, using an established ligand, {alpha}2M*, as a positive control. Fig. 3GoB indicates that RAP, at a 100-fold molar excess, did not inhibit GRP94 binding to elicited macrophages. Importantly, under identical assay conditions, {alpha}2M* binding was efficiently blocked by RAP (Fig. 3GoC). The inhibition of GRP94 binding by RAP was not due to GRP94 displaying a higher affinity for APCs than {alpha}2M*, as GRP94 exhibits an overall Kd of ~2 x 10-7 M to elicited macrophages (Fig. 2GoB, inset), as compared with a low nanomolar Kd for {alpha}2M* binding to CD91 (36). The effects of RAP on cell surface binding of fluorescein-labeled GRP94 and Texas Red-labeled {alpha}2M* was also examined by confocal microscopy (Fig. 3Go, D and E). Consistent with the FACS data, RAP was without effect on GRP94 binding (green channel), whereas {alpha}2M* binding (red channel) was efficiently blocked (Fig. 3Go, compare D, minus RAP, with E, plus RAP). Finally, we tested whether {alpha}2M* directly blocked the re-presentation of GRP94-associated peptides. In these experiments, it was observed that SIINFEKL peptide, complexed with GRP94, was re-presented both in the presence of {alpha}2M-containing serum and in the presence of serum supplemented with 100 µg/ml {alpha}2M* (Fig. 3GoF), a level previously reported to abolish GRP94-dependent cross-priming of T cells (12).



View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 3. GRP94 binding to macrophages is not inhibited by the CD91 antagonist RAP, nor is peptide re-presentation suppressed by {alpha}2M*. A, Elicited peritoneal macrophages were assayed by FACS analysis for their ability to bind 25 nM GRP94 (B) or {alpha}2M* (C) in absence or presence of a 100-fold molar excess of RAP. As illustrated in D and E, RAP competition of {alpha}2M* but not GRP94 was confirmed by confocal microscopy. These experiments were conducted identically to those illustrated in A–C. F, Elicited peritoneal macrophages were incubated in the presence of 50 µg/ml GRP94-OVA complex in the absence (GRP94/OVA), or the presence of 100 µg/ml {alpha}2M* (GRP94/OVA/{alpha}2M) for 3 h at 37°C. Peptide re-presentation was assessed by subsequent staining with the Kb-OVA-specific Ab 25-D1.16 and FACS analysis. Also shown is 25-D1.16 staining of macrophages incubated in the absence of GRP94-OVA.

 
In noting the marked time interval differences in assays of peptide re-presentation on cell surface class I molecules (<=3 h) and GRP94-mediated T cell activation (>20 h) (12), it should be considered that the reported inhibition of T cell activation by CD91 Ab and {alpha}2M may reflect physiological responses of the cells to prolonged culture with these reagents. For example, ligand-bound CD91 elicits pronounced cell activation; thus, we suggest that CD91 Ab and {alpha}2M may disrupt the ability of APC to activate cognate T cells (37, 38, 39).

In summary, the included data indicate that macrophage CD91 displays biochemical properties consistent with its role as a {alpha}2M* receptor. However, the lack of a positive correlation between CD91 expression and GRP94 cell surface binding, the absence of colocalization between GRP94 and CD91 in the early trafficking itinerary of the two proteins, the inability of {alpha}2M* to inhibit the binding or internalization of GRP94 or the re-presentation of its associated peptides, and the observation that RAP, a biological antagonist for CD91 receptor ligands, is without effect on GRP94 binding argue strongly against a role for CD91 in the receptor-mediated internalization of GRP94. From these data, it is equally evident that APCs bear cell surface receptors that are capable of directing GRP94 into the class I Ag re-presentation pathway.


   Acknowledgments
 
We thank the Duke University University Medical Center Comprehensive Cancer Center Shared Flow Cytometry Facility for FACS analyses and acknowledge the support of the Duke University Medical Center Comprehensive Cancer Center Shared Confocal Microscopy Facility.


   Footnotes
 
1 This work was supported by National Institutes of Health Grant DK53058 (to C.V.N.) and HL24066 (to S.P.), National Research Service Award Fellowship 1F32CA9016901 (to B.B.), and the H. H. Gibson Cancer Fellowship (to B.B.). Back

2 Address correspondence and reprint requests to Dr. Christopher V. Nicchitta, Department of Cell Biology, Duke University Medical Center, Durham, NC 27710. E-mail address: c.nicchitta{at}cellbio.duke.edu Back

3 Abbreviations used in this paper: LDL, low-density lipoprotein; RAP, receptor-associated protein; {alpha}2M, {alpha}2-macroglobulin; CHO, Chinese hamster ovary. Back

Received for publication January 11, 2002. Accepted for publication February 27, 2002.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Yamazaki, K., T. Nguyen, E. R. Podack. 1999. Cutting edge: tumor-secreted heat shock-fusion protein elicits CD8 cells for rejection. J. Immunol. 163:5178.[Abstract/Free Full Text]
  2. Zheng, H., J. Dai, D. Stoilova, Z. Li. 2001. Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J. Immunol. 167:6731.[Abstract/Free Full Text]
  3. Srivastava, P. K., H. Udono. 1994. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6:728.[Medline]
  4. Srivastava, P. K., L. J. Old. 1988. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol. Today 9:78.[Medline]
  5. Tamura, Y., P. Peng, K. Liu, M. Daou, P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117.[Abstract/Free Full Text]
  6. Singh-Jasuja, H., H. U. Scherer, N. Hilf, D. Arnold-Schild, H. G. Rammensee, R. E. Toes, H. Schild. 2000. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 30:2211.[Medline]
  7. Basu, S., R. J. Binder, R. Suto, K. M. Anderson, P. K. Srivastava. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-{kappa}B pathway. Int. Immunol. 12:1539.[Abstract/Free Full Text]
  8. Singh-Jasuja, H., R. E. Toes, P. Spee, C. Munz, N. Hilf, S. P. Schoenberger, P. Ricciardi-Castagnoli, J. Neefjes, H. G. Rammensee, D. Arnold-Schild, H. Schild. 2000. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 191:1965.[Abstract/Free Full Text]
  9. Srivastava, P. K., R. J. Amato. 2001. Heat shock proteins: the "Swiss army knife" vaccines against cancers and infectious agents. Vaccine 19:2590.[Medline]
  10. Lammert, E., D. Arnold, M. Nijenhuis, F. Momburg, G. J. Hammerling, J. Brunner, S. Stevanovic, H. G. Rammensee, H. Schild. 1997. The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur. J. Immunol. 27:923.[Medline]
  11. Argon, Y., B. B. Simen. 1999. GRP94, an ER chaperone with protein and peptide binding properties. Semin. Cell Dev. Biol. 10:495.[Medline]
  12. Binder, R. J., D. K. Han, P. K. Srivastava. 2000. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1:151.[Medline]
  13. Basu, S., R. J. Binder, T. Ramalingam, P. K. Srivastava. 2001. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303.[Medline]
  14. Binder, R. J., D. Karimeddini, P. K. Srivastava. 2001. Adjuvanticity of {alpha}2-macroglobulin, an independent ligand for the heat shock protein receptor CD91. J. Immunol. 166:4968.[Abstract/Free Full Text]
  15. Chu, C. T., S. V. Pizzo. 1994. {alpha}2-Macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation. Lab. Invest. 71:792.[Medline]
  16. Herz, J., J. L. Goldstein, D. K. Strickland, Y. K. Ho, M. S. Brown. 1991. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/{alpha}2-macroglobulin receptor. J. Biol. Chem. 266:21232.[Abstract/Free Full Text]
  17. Bu, G., M. P. Marzolo. 2000. Role of RAP in the biogenesis of lipoprotein receptors. Trends Cardiovasc. Med. 10:148.[Medline]
  18. Williams, S. E., J. D. Ashcom, W. S. Argraves, D. K. Strickland. 1992. A novel mechanism for controlling the activity of {alpha}2-macroglobulin receptor/low density lipoprotein receptor-related protein: multiple regulatory sites for 39-kDa receptor-associated protein. J. Biol. Chem. 267:9035.[Abstract/Free Full Text]
  19. Bu, G., H. J. Geuze, G. J. Strous, A. L. Schwartz. 1995. 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J. 14:2269.[Medline]
  20. Wearsch, P. A., C. V. Nicchitta. 1996. Purification and partial molecular characterization of GRP94, an ER resident chaperone. Protein Expression Purif. 7:114.[Medline]
  21. Gron, H., S. V. Pizzo. 1998. Nonproteolytic incorporation of protein ligands into human {alpha}2-macroglobulin: implications for the binding mechanism of {alpha}2-macroglobulin. Biochemistry 37:6009.[Medline]
  22. Howard, G. C., U. K. Misra, D. L. DeCamp, S. V. Pizzo. 1996. Altered interaction of cis-dichlorodiammineplatinum(II)-modified {alpha}2-macroglobulin ({alpha}2M) with the low density lipoprotein receptor-related protein/{alpha}2M receptor but not the {alpha}2M signaling receptor. J. Clin. Invest. 97:1193.[Medline]
  23. Wassenberg, J. J., C. Dezfulian, C. V. Nicchitta. 1999. Receptor mediated and fluid phase pathways for internalization of the ER Hsp90 chaperone GRP94 in murine macrophages. J. Cell Sci. 112:2167.[Abstract]
  24. Blachere, N. E., Z. Li, R. Y. Chandawarkar, R. Suto, N. S. Jaikaria, S. Basu, H. Udono, P. K. Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186:1315.[Abstract/Free Full Text]
  25. Suto, R., P. K. Srivastava. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585.[Abstract/Free Full Text]
  26. Berwin, B., M. F. N. Rosser, K. G. Brinker, and C. V. Nicchitta. 2002. Transfer of GRP94(gp96)-associated peptides onto endosomal MHC class I molecules. Traffic. In press.
  27. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal Ab. Immunity 6:715.[Medline]
  28. Krieger, M., J. Herz. 1994. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem. 63:601.[Medline]
  29. Willnow, T. E., J. Herz. 1994. Genetic deficiency in low density lipoprotein receptor-related protein confers cellular resistance to Pseudomonas exotoxin A: evidence that this protein is required for uptake and degradation of multiple ligands. J. Cell Sci. 107:719.[Abstract]
  30. Quinn, K. A., P. G. Grimsley, Y. P. Dai, M. Tapner, C. N. Chesterman, D. A. Owensby. 1997. Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J. Biol. Chem. 272:23946.[Abstract/Free Full Text]
  31. Hussaini, I. M., J. LaMarre, J. J. Lysiak, L. R. Karns, S. R. VandenBerg, S. L. Gonias. 1996. Transcriptional regulation of LDL receptor-related protein by IFN-{gamma} and the antagonistic activity of TGF-{beta}1 in the RAW 264.7 macrophage-like cell line. J. Leukocyte Biol. 59:733.[Abstract]
  32. FitzGerald, D. J., C. M. Fryling, A. Zdanovsky, C. B. Saelinger, M. Kounnas, J. A. Winkles, D. Strickland, S. Leppla. 1995. Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein. J. Cell Biol. 129:1533.[Abstract/Free Full Text]
  33. Misra, U. K., C. T. Chu, G. Gawdi, S. V. Pizzo. 1994. Evidence for a second {alpha}2-macroglobulin receptor. J. Biol. Chem. 269:12541.[Abstract/Free Full Text]
  34. Ganea, D., S. Dray, M. Teodorescu. 1983. {alpha}-macroglobulins: enzyme-binding proteins modulating lymphocyte function. Surv. Immunol. Res. 2:367.[Medline]
  35. Adlakha, C. L., J. P. Hart, S. V. Pizzo. 2001. Kinetics of nonproteolytic incorporation of a protein ligand into thermally activated {alpha}2-macroglobulin: evidence for a novel nascent state. J. Biol. Chem. 276:41547.[Abstract/Free Full Text]
  36. Howard, G. C., Y. Yamaguchi, U. K. Misra, G. Gawdi, A. Nelsen, D. L. DeCamp, S. V. Pizzo. 1996. Selective mutations in cloned and expressed {alpha}-macroglobulin receptor binding fragment alter binding to either the {alpha}2-macroglobulin signaling receptor or the low density lipoprotein receptor-related protein/{alpha}2-macroglobulin receptor. J. Biol. Chem. 271:14105.[Abstract/Free Full Text]
  37. Misra, U. K., G. Gawdi, S. V. Pizzo. 1995. Ligation of the {alpha}2-macroglobulin signalling receptor on macrophages induces protein phosphorylation and an increase in cytosolic pH. Biochem. J. 309:151.
  38. Misra, U. K., C. T. Chu, D. S. Rubenstein, G. Gawdi, S. V. Pizzo. 1993. Receptor-recognized {alpha}2-macroglobulin-methylamine elevates intracellular calcium, inositol phosphates and cyclic AMP in murine peritoneal macrophages. Biochem. J. 290:885.
  39. Howard, G. C., B. C. Roberts, D. L. Epstein, S. V. Pizzo. 1996. Characterization of {alpha}2-macroglobulin binding to human trabecular meshwork cells: presence of the {alpha}2-macroglobulin signaling receptor. Arch. Biochem. Biophys. 333:19.[Medline]



This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
E. Amiel, A. Alonso, S. Uematsu, S. Akira, M. E. Poynter, and B. Berwin
Pivotal Advance: Toll-like receptor regulation of scavenger receptor-A-mediated phagocytosis
J. Leukoc. Biol., April 1, 2009; 85(4): 595 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
A. P. Lillis, L. B. Van Duyn, J. E. Murphy-Ullrich, and D. K. Strickland
LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout Studies
Physiol Rev, July 1, 2008; 88(3): 887 - 918.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. R. Theriault, H. Adachi, and S. K. Calderwood
Role of Scavenger Receptors in the Binding and Internalization of Heat Shock Protein 70
J. Immunol., December 15, 2006; 177(12): 8604 - 8611.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. W. Graner and D. D. Bigner
Chaperone proteins and brain tumors: Potential targets and possible therapeutics
Neuro-oncol, July 1, 2005; 7(3): 260 - 278.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
R. Demine and P. Walden
Testing the Role of gp96 as Peptide Chaperone in Antigen Processing
J. Biol. Chem., May 6, 2005; 280(18): 17573 - 17578.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Berwin, Y. Delneste, R. V. Lovingood, S. R. Post, and S. V. Pizzo
SREC-I, a Type F Scavenger Receptor, Is an Endocytic Receptor for Calreticulin
J. Biol. Chem., December 3, 2004; 279(49): 51250 - 51257.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. A. Tobar, P. A. Gonzalez, and A. M. Kalergis
Salmonella Escape from Antigen Presentation Can Be Overcome by Targeting Bacteria to Fc{gamma} Receptors on Dendritic Cells
J. Immunol., September 15, 2004; 173(6): 4058 - 4065.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. J. Binder and P. K. Srivastava
Essential role of CD91 in re-presentation of gp96-chaperoned peptides
PNAS, April 20, 2004; 101(16): 6128 - 6133.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
U. K. Rapp and S. H. Kaufmann
DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen
Int. Immunol., April 1, 2004; 16(4): 597 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
R. Y. Chandawarkar, M. S. Wagh, J. T. Kovalchin, and P. Srivastava
Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis
Int. Immunol., April 1, 2004; 16(4): 615 - 624.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. C. Baker-LePain, M. Sarzotti, and C. V. Nicchitta
Glucose-Regulated Protein 94/Glycoprotein 96 Elicits Bystander Activation of CD4+ T Cell Th1 Cytokine Production In Vivo
J. Immunol., April 1, 2004; 172(7): 4195 - 4203.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Stebbing, B. Gazzard, S. Portsmouth, F. Gotch, L. Kim, M. Bower, S. Mandalia, R. Binder, P. Srivastava, and S. Patterson
Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor
Blood, September 1, 2003; 102(5): 1806 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. P. Radsak, N. Hilf, H. Singh-Jasuja, S. Braedel, P. Brossart, H.-G. Rammensee, and H. Schild
The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions
Blood, April 1, 2003; 101(7): 2810 - 2815.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Vogen, T. Gidalevitz, C. Biswas, B. B. Simen, E. Stein, F. Gulmen, and Y. Argon
Radicicol-sensitive Peptide Binding to the N-terminal Portion of GRP94
J. Biol. Chem., October 18, 2002; 277(43): 40742 - 40750.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
T. Becker, F.-U. Hartl, and F. Wieland
CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes
J. Cell Biol., September 29, 2002; 158(7): 1277 - 1285.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berwin, B.
Right arrow Articles by Nicchitta, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berwin, B.
Right arrow Articles by Nicchitta, C. V.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS